OSI, AVEO sign small molecules pact

OSI Pharmaceuticals and AVEO Pharmaceuticals have inked a deal to discover and develop small molecules. The companies hope to develop therapies that target the underlying mechanisms of epithelial-mesenchymal transition in cancer. AVEO gains $10 million upfront and purchase equity valued at approximately $5 million. OSI will also pay AVEO research funding, as well as milestones and royalties for any successful therapies that result from the pact. 

- see the release on the deal for more

Related Articles:
AVEO designs better mice to trap better therapies. Report
AVEO gains $53M in financing. Report
OSI looks to unload Macugen, exit eye diseases. Report
OSI licenses diabetes drug to Lilly in $385M pact. Report

Suggested Articles

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.